Chronic Myeloid Leukemia
Grupo Espanol De Leucemia Mieloide Cronica (GELMC) focuses on BCR-ABL1-positive chronic myeloid leukemia, with interest in adult patients in the early chronic phase and treatment strategies aimed at deep molecular responses.
- Asciminib in first-line therapy
- Combination treatment with nilotinib
- Deep molecular response and MR4
- Early chronic phase disease management
The sponsor’s clinical research activity is centered on therapeutic options for Philadelphia chromosome-positive leukemia across collaborative sites in Spain and other participating countries.
